Illumina, Inc. $ILMN Shares Acquired by M&G PLC

M&G PLC boosted its position in Illumina, Inc. (NASDAQ:ILMN) by 130.6% during the 2nd quarter, Holdings Channel reports. The fund owned 558,503 shares of the life sciences company’s stock after acquiring an additional 316,331 shares during the quarter. M&G PLC’s holdings in Illumina were worth $53,058,000 as of its most recent SEC filing.

Other institutional investors also recently added to or reduced their stakes in the company. Cerity Partners LLC raised its holdings in shares of Illumina by 2.6% in the 1st quarter. Cerity Partners LLC now owns 25,951 shares of the life sciences company’s stock valued at $2,059,000 after purchasing an additional 661 shares in the last quarter. Xponance Inc. raised its stake in Illumina by 1.0% in the first quarter. Xponance Inc. now owns 26,762 shares of the life sciences company’s stock valued at $2,123,000 after buying an additional 264 shares in the last quarter. Ballentine Partners LLC raised its stake in Illumina by 29.9% in the first quarter. Ballentine Partners LLC now owns 2,603 shares of the life sciences company’s stock valued at $207,000 after buying an additional 599 shares in the last quarter. New York State Common Retirement Fund lifted its holdings in Illumina by 36.8% during the 1st quarter. New York State Common Retirement Fund now owns 138,993 shares of the life sciences company’s stock worth $11,028,000 after buying an additional 37,388 shares during the last quarter. Finally, Stephens Inc. AR boosted its position in shares of Illumina by 12.4% during the 1st quarter. Stephens Inc. AR now owns 7,447 shares of the life sciences company’s stock worth $591,000 after acquiring an additional 824 shares in the last quarter. Hedge funds and other institutional investors own 89.42% of the company’s stock.

Illumina Stock Up 0.7%

ILMN stock opened at $122.60 on Wednesday. Illumina, Inc. has a 12 month low of $68.70 and a 12 month high of $153.06. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.81 and a quick ratio of 1.41. The company has a market cap of $18.73 billion, a price-to-earnings ratio of 15.52, a price-to-earnings-growth ratio of 2.34 and a beta of 1.42. The company has a fifty day moving average price of $101.44 and a 200 day moving average price of $95.20.

Illumina (NASDAQ:ILMN) last released its quarterly earnings results on Thursday, October 30th. The life sciences company reported $1.34 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.16 by $0.18. The firm had revenue of $1.08 billion for the quarter, compared to analyst estimates of $1.07 billion. Illumina had a return on equity of 28.93% and a net margin of 29.36%.The business’s revenue was up .4% on a year-over-year basis. During the same quarter last year, the company posted $1.14 earnings per share. Illumina has set its FY 2025 guidance at 4.650-4.750 EPS. Sell-side analysts expect that Illumina, Inc. will post 4.51 earnings per share for the current year.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on the company. Barclays raised their target price on Illumina from $95.00 to $100.00 and gave the stock an “underweight” rating in a research report on Friday, October 31st. TD Cowen raised their price objective on shares of Illumina from $110.00 to $115.00 and gave the stock a “hold” rating in a report on Friday, October 31st. Daiwa Capital Markets cut shares of Illumina from an “outperform” rating to a “neutral” rating and set a $94.00 target price for the company. in a report on Tuesday, August 12th. Cowen reiterated a “hold” rating on shares of Illumina in a research note on Friday, October 31st. Finally, UBS Group upped their price objective on shares of Illumina from $110.00 to $120.00 and gave the company a “neutral” rating in a research note on Friday, October 31st. Five research analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and three have given a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $115.00.

Insider Activity

In related news, Director Scott Gottlieb bought 500 shares of the company’s stock in a transaction dated Monday, November 3rd. The shares were acquired at an average price of $122.13 per share, with a total value of $61,065.00. Following the completion of the acquisition, the director owned 12,523 shares in the company, valued at approximately $1,529,433.99. This trade represents a 4.16% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 2.60% of the company’s stock.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.